Why the Treatment Sequence Matters: Interplay Between Chemotherapy Cycles received, Cumulative dose Intensity, and Survival in Resected Early-Stage Pancreas Cancer.

Victoria S Wu,Mohamedraed Elshami,Henry J Stitzel, Jonathan J Lee,Jonathan J Hue,Ravi K Kyasaram,Jeffrey M Hardacre,John B Ammori,Jordan M Winter,J Eva Selfridge,Amr Mohamed,Sakti Chakrabarti,David Bajor,Amit Mahipal,Lee M Ocuin

Annals of surgery（2023）

引用 2|浏览10

暂无评分

摘要

Patients with PDAC who received ≥67% of recommended chemotherapy cycles or ≥56% cumulative RDI had improved OS. Neoadjuvant therapy was associated with increased odds of receiving ≥67% of cycles and ≥56% cumulative RDI and should be considered in all patients with resectable PDAC.

查看译文

关键词

chemotherapy cycles, pancreatic adenocarcinoma, pancreatectomy, relative dose intensity, survival, treatment sequence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要